调气化浊法治疗慢性阻塞性肺疾病急性加重期合并2型糖尿病痰瘀互结兼气阴两虚证临床研究OA
目的 观察调气化浊法治疗慢性阻塞性肺疾病急性加重期(AECOPD)合并 2 型糖尿病(T2DM)痰瘀互结兼气阴两虚证患者的临床疗效.方法 选取2022 年10 月至2023 年12 月安徽省淮北市中医医院肺病科(68 例)和糖尿病科(28 例)AECOPD合并T2DM痰瘀互结兼气阴两虚证患者共 96 例,按随机数字表法分为治疗组和对照组,每组 48例.对照组采用常规西医治疗,治疗组在对照组基础上加服柴葶宁肺颗粒和丹蛭降糖胶囊.比较 2 组治疗前后中医证候积分、肺功能、血气分析、血糖指标、中文版疾病进展恐惧简化量表(FoP-Q-SF)评分、COPD患者自我评估测试(CAT)评分及安全指标.结果 治疗后,2 组中医证候积分、FoP-Q-SF量表、CAT评分、血糖指标[糖化血红蛋白(HbA1c)、空腹血糖(FPG)、餐后 2h血糖(2 hPG)]水平均较治疗前下降(P<0.05),且治疗组低于对照组(P<0.05).治疗后 2 组肺功能指标用力肺活量(FVC)、第1s用力呼气容积(FEV1)及FEV1/FVC均较治疗前升高(P<0.05),且治疗组均高于对照组(P<0.05).治疗后 2 组血气分析中氧分压(PaO2)、血氧饱和度(SaO2)均升高(P<0.05),二氧化碳分压(PaCO2)均下降(P<0.05),且治疗组PaO2、SaO2 高于对照组(P<0.05),PaCO2 低于对照组(P<0.05).2 组均未见明显不良反应.结论 调气化浊法治疗AECOPD合并T2DM患者,能有效改善患者肺功能、血气指标、血糖指标、生活质量及中医证候积分,且安全性高.
Objective To observe the clinical effect of regulating gasification and turbidity on acute exacerbation of chronic obstructive pulmonary disease(AECOPD)patients with type 2 diabetes mellitus(T2DM)in the syndrome of phlegm and blood stasis plus Qi and Yin deficiencies.Methods A total of 96 AECOPD patients with T2DM in the syndrome of phlegm and blood stasis plus Qi and Yin deficiencies treated in the Department of Pulmonary Diseases(68 cases)and Department of Diabetes(28 cases)of Huaibei Hospital of Traditional Chinese Medicine from October 2022 and December 2023 were included.They were randomly divided into the treatment group and control group,with 48 cases in each group.Patients in both groups received routine Western medicine treatment,while those in the treatment group additionally received Chaiting Ningfei Granules and Danzhi Jiangtang Capsules.The TCM syndrome scores,lung function,blood gas analysis,blood glucose indicators,the fear of progression questionnaire--short form in Chinese version(FoP-Q-SF),the COPD Assessment Test(CAT),and safety indicators were compared between the two groups before and after treatment.Results After treatment,TCM syndrome,FoP-Q-SF and CAT scores,and blood sugar indicators(glycated hemoglobin[HbA1c],fasting plasma glucose[FPG],and 2 h postprandial blood sugar[2 hPG])were significantly reduced in both groups(P<0.05),which were significantly lower in the treatment group than the control group(P<0.05).After treatment,the forced vital capacity(FVC),forced expiratory volume in the first second(FEV1),and FEV1/FVC were significantly elevated in both groups(P<0.05),which were significantly higher in the treatment group than the control group(P<0.05).After treatment,significantly higher oxygen partial pressure(PaO2)and oxygen saturation(SaO2),and lower carbon dioxide partial pressure(PaCO2)were detected in both groups(P<0.05),which were significantly pronounced in the treatment group than the control group(P<0.05).No adverse reactions occurred during the clinical trial in both groups.Conclusion For AECOPD patients with T2DM,regulating gasification and turbidity can effectively improve lung function,blood gas indexes,blood sugar indexes,quality of life and TCM syndrome scores,and with high safety.
郑彩霞;方朝晖;于盼;程若东;许成群;朱雪娜
安徽省淮北市中医医院肺病科,安徽 淮北 235000安徽中医药大学第一附属医院内分泌科,安徽 合肥 230031安徽省淮北市中医医院肺病科,安徽 淮北 235000安徽省淮北市中医医院肺病科,安徽 淮北 235000安徽省淮北市中医医院糖尿病科,安徽 淮北 235000安徽省淮北市中医医院肺病科,安徽 淮北 235000
医药卫生
肺疾病,慢性阻塞性糖尿病,2型痰瘀互结气阴两虚调气化浊法
Chronic obstructive pulmonary diseaseType 2 diabetes mellitusPhlegm and blood stasisQi and Yin deficienciesRegulating gasification and turbidity
《河北中医》 2026 (1)
52-56,61,6
2022年度安徽省卫生健康科研项目(编号:AHWJ2022b115)2022年度安徽省博士后科研人员科研活动经费资助项目(编号:2022B586)2022年度安徽省中医药传承创新科研项目(编号:2022CCYB17)安徽中医药大学2021年度临床科研项目(编号:2021LCHB02)
评论